This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:othertreatments:antitnf [11.02.2009] – marysue | home:othertreatments:antitnf [06.05.2010] – paulalbert | ||
---|---|---|---|
Line 1: | Line 1: | ||
====== Anti-TNF drugs ====== | ====== Anti-TNF drugs ====== | ||
- | <html>< | + | <relatedarticle> [[home: |
Line 30: | Line 30: | ||
==== Olmesartan (Benicar) vs. TNF-alpha blockers ==== | ==== Olmesartan (Benicar) vs. TNF-alpha blockers ==== | ||
- | <html>< | + | <relatedarticle> [[home: |
Line 65: | Line 65: | ||
To reduce the likelihood of contracting or exacerbating tuberculosis, | To reduce the likelihood of contracting or exacerbating tuberculosis, | ||
- | Fatal fungal | + | " |
Researchers have also observed reactivation of latent viral infections, namely hepatitis B in patients who are chronic carriers of the virus. | Researchers have also observed reactivation of latent viral infections, namely hepatitis B in patients who are chronic carriers of the virus. |